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Chromobox 7 (CBX7) is a chromobox family protein and a compo-
nent of the Polycomb repressive complex 1 (PRC1) that extends the
lifespan of cultured epithelial cells and can act independently of
BMI-1 to repress the INK4a/ARF tumor suppressor locus. To deter-
mine whether CBX7 might be oncogenic, we examined its expres-
sion pattern in a range of normal human tissues and tumor
samples. CBX7 was expressed at high levels in germinal center
lymphocytes and germinal center-derived follicular lymphomas,
where elevated expression correlated with high c-Myc expression
and a more advanced tumor grade. By targeting Cbx7 expression
to the lymphoid compartment in mice, we showed that Cbx7 can
initiate T cell lymphomagenesis and cooperate with c-Myc to
produce highly aggressive B cell lymphomas. Furthermore, Cbx7
repressed transcription from the Ink4a/Arf locus and acted epistati-
cally to the Arf-p53 pathway during tumorigenesis. These data
identify CBX7 as a chromobox protein causally linked to cancer
development and may help explain the low frequency of INK4a/
ARF mutations observed in human follicular lymphoma.
Ink4a-ARF  oncogene  Polycomb  follicular lymphoma  p53
Polycomb (Pc) group (PcG) proteins are a class of epigeneticregulators that, despite being structurally unrelated, can be
grouped functionally into two major multiprotein complexes
referred to as Pc repressive complex 1 and 2 (PRC1 and PRC2).
The PRC2 complex has histone deacetylase and histone methyl
transferase activities (specific for K27 of histone H3) and
establishes histone repressive marks on the chromatin (1). These
marks are subsequently read by PRC1 complexes that alter
higher chromatin organization, ultimately leading to transcrip-
tional repression (2, 3). Although the precise composition of
these two complexes may vary according to cellular context (4),
the core components of the mammalian PRC1 complex are the
homologs of Drosophila Pc, Posterior sex combs, Sex combs
extra, and Polyhomeiotic. The PRC2 complex consists of En-
hancer of Zeste (EZH2), Early Embryonic-Deficient (EED),
Suppressor of Zeste (SUZ12), and other associated proteins.
PcG proteins regulate morphogenesis, chromosome X-inacti-
vation, hematopoiesis, stem-cell self renewal, and cellular pro-
liferation (reviewed in refs. 5 and 6). In addition, several PcG
proteins have been linked to tumorigenesis (7, 8). BMI-1, one of
the six mammalian orthologs of Drosophila Psc, is the PcG gene
most strongly associated with cancer and was initially identified
for its ability to cooperate with c-Myc in lymphomagenesis (9,
10). Furthermore, BMI-1 is overexpressed in mantle cell lym-
phoma and several other malignancies (11). Bmi-1 can extend
proliferative lifespan, reduce apoptosis, and promote transfor-
mation of cultured cells and tumorigenesis in mice (12–14).
These properties depend on its ability to repress transcription
from the Ink4a/Arf tumor suppressor locus (13), which controls
cellular senescence and apoptosis through regulating the Rb and
p53 tumor suppressors (15). Other PcG proteins such as EZH2
and SUZ12 are also associated with tumorigenesis (7), but none
of these has been validated as oncogenes in vivo.
The Pc homolog Chromobox 7 (CBX7) was identified by
virtue of its ability to extend the lifespan of primary human
prostate epithelial cells (16). CBX7 shares no homology with
BMI-1 but belongs to a mammalian family of chromobox-
containing proteins that comprises three homologs of HP1 and
five homologs of Pc. Although CBX7 can also repress the
INK4a/ARF locus, it can function independently of BMI-1 (16).
Here, we demonstrate that CBX7 is up-regulated in follicular
lymphoma and possesses oncogenic properties in the hemato-
poietic compartment, thus identifying CBX7 as a potential
human oncogene.
Results
Elevated Expression of CBX7 in Human Follicular Lymphoma. To
explore the involvement of CBX7 in human cancer, we examined
its expression in the ONCOMINE database (17). Analyzing data
from a multicancer study (18), we noted that CBX7 was ex-
pressed at significantly higher levels in follicular lymphoma
relative to normal germinal center cells, from which follicular
lymphoma arises (P  3.8  105). The association between
CBX7 expression and follicular lymphoma (Q 5.3 103) was
even more significant than for BCL-2 expression (Q  1.6 
102), a striking result given that t(14; 18) translocations involv-
ing BCL-2 are a hallmark of this disease, and 90% of indolent
follicular lymphomas express high levels of BCL-2 (19). In
accordance with previous reports (11), we did not observe an
association between BMI-1 expression and follicular lymphoma
(Fig. 1A). Furthermore, no other PcG gene analyzed was sig-
nificantly increased in this data set [supporting information (SI)
Table 1].
To extend these observations, we analyzed CBX7 levels by
immunohistochemistry (IHC) using tissue microarrays that con-
tained 168 cases of follicular lymphoma. To this end, we used a
previously described polyclonal antibody specific for CBX7 (16)
and validated for IHC (20) (see also SI Fig. 5 for further
analyses). A subset of samples (54%) displayed strong or mod-
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erate levels of CBX7 staining (Fig. 1 B and C). Using Fisher’s
exact test, a statistically significant correlation was observed
between CBX7 expression and Ki67 (P  0.015) and between
CBX7 expression and higher-grade follicular lymphoma (P 
0.0004) (SI Table 2). Consistent with the microarray data, a
subset of lymphomas with high CBX7 levels displayed overex-
pression of CBX7 transcripts as assessed by quantitative RT-
PCR analysis of paraffin shavings. These same samples showed
no evidence of increased copy number of the CBX7 gene or
translocation at the CBX7 locus (22q13), suggesting that high
CBX7 levels arise at least in part from increased transcription or
mRNA stability (SI Fig. 6 and data not shown).
Elevated CBX7 expression also correlated with the presence
of t(14;18) translocations (P  0.045) involving BCL-2, a hall-
mark of follicular lymphoma, and positive immunostaining for
ZBTB7 (also known as Pokemon) (P  0.007) (21) and c-MYC
(P  0.007), both markers of poor prognosis in follicular
lymphoma (22, 23). However, only one of eight cases coexpress-
ing high CBX7 and c-MYC protein was associated with a
translocation of the c-MYC gene. Apart from follicular lym-
phoma, no evidence for consistent up-regulation of CBX7 was
observed in a limited survey of other solid tumors and lymphoma
subtypes, including mantle cell lymphoma, with the possible
exception of a subset of diffuse large B cell lymphomas (data not
shown).
CBX7 Expression in the Germinal Center. The germinal center
contains a complex microenvironment that provides a niche for
B cell differentiation. Different PcG proteins present distinct
patterns of expression in germinal centers and play a key role in
the generation and maturation of B and T cells (5). We therefore
analyzed BMI-1 and CBX7 expression in the germinal centers of
normal tonsils. Consistent with previous reports (5), BMI-1 was
expressed predominantly in mantle zone (MZ) lymphocytes and
to a lesser extent in centrocytes and scattered centroblasts in the
dark zone (DZ) and the light zone within the germinal center (SI
Fig. 7). In contrast, CBX7 was rarely expressed in MZ lympho-
cytes but accumulated in the germinal center with high expres-
sion in histiocytes and lower expression in centrocytes and
scattered centroblasts, most predominantly in the DZ (Fig. 1D).
Although the CBX7 levels observed in CBX7-positive follicular
lymphomas were higher than in normal germinal center cells,
from expression data alone, it is difficult to judge whether CBX7
contributes directly to tumorigenesis or represents a marker of
the cell of origin of this malignancy. A similar situation applies
to BMI-1 (11), which is expressed at high levels in mantle cell
lymphomas (derived from the MZ) but not in follicular lym-
phoma (derived from germinal center cells).
CBX7 Promotes Lymphomagenesis. That CBX7 appeared to be
aberrantly expressed in human lymphoma prompted us to test
whether it could promote lymphomagenesis in mice. To this end,
we produced transgenic chimeric mice by introducing genes into
hematopoietic stem cells (HSCs) or early progenitor cells using
recombinant retroviruses followed by adoptive transfer into
irradiated recipients (SI Fig. 8A). By using different retroviruses
or target cell populations, it is possible to assess the impact of
genes and gene combinations in a manner that is much more
rapid than traditional germ-line transgenic methods. Moreover,
the expression of each gene is strictly confined to the hemato-
poietic compartment, and the coexpressed GFP reporter allows
identification of transgene-expressing cells and tumor imaging.
In contrast to germ-line transgenic mice, gene function is studied
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Fig. 1. Aberrant expression of CBX7 in human follicular lymphomas. (A) Expression of CBX7, BCL-2, and BMI-1 in germinal center (GC, green) and follicular
lymphoma (FL, red), as reported in ref. 18. (B) FL samples were stained by IHC by using anti-CBX7 antibodies and the CBX7 levels evaluated and quantified as
explained in Materials and Methods. (C) Representative pictures of FL samples stained with CBX7 antibodies are shown. (D) CBX7 expression in secondary GC
of the tonsil. Arrows indicate high CBX7 expression in germinal center histiocytes.
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in a chimeric setting, where developing tumor cells are sur-
rounded by their normal counterparts.
We produced a murine stem cell virus (MSCV) vector that
coexpressedmurine Cbx7 with GFP and efficiently expressed the
Cbx7 protein. Moreover, enforced expression of Cbx7 from this
vector was capable of overcoming Ras-induced senescence and
c-Myc-induced apoptosis of rodent fibroblasts, leading to an
increase in their oncogenic transformation (SI Fig. 9). A signif-
icant proportion of mice reconstituted with Cbx7-expressing
HSCs derived fromC57BL/6WTmice (11/30) developed tumors
within 1 year of adoptive transfer (Fig. 2A). The affected animals
invariably displayed an enlarged thymus and splenomegaly (data
not shown). In contrast, none of the animals reconstituted with
HSCs harboring the control vector showed signs of tumor
development (Fig. 2A and SI Fig. 8B), excluding insertional
mutagenesis as the cause of the observed pathologies. Cbx7-
expressing tumors were disseminated T cell lymphomas with a
high proliferative index (Ki67) and a low apoptotic rate (as
assessed by TUNEL) (Fig. 2B). Characterization of Cbx7-
expressing lymphomas by FACS showed they were invariably
GFP-positive and a mature CD4- or CD8-positive T cell type
(data not shown). Interestingly, E-Bmi-1 transgenic mice de-
velop both B and T cell lymphomas with a similar latency to that
observed upon Cbx7 expression, although these tumors were
immature in nature (24). T (and B) cell lymphomas were also
observed in Ink4a/Arf/ mice (25).
Cbx7 Cooperates with Myc to Produce Aggressive Lymphomas. The
long latency and incomplete penetrance observed after overex-
pression of Cbx7 suggest that aberrant Cbx7 expression is not
sufficient for lymphomagenesis. Our immunohistochemical
analysis indicated that human follicular lymphomas with ele-
vated CBX7 expression often overexpressed c-MYC (see SI
Table 2), and immunoblotting of Cbx7 induced lymphomas
indicated that two of four also up-regulated c-Myc through an
unknown mechanism (Fig. 2C; see Cbx7 lymphomas 2 and 4). To
test whether Cbx7 can cooperate with c-Myc, we performed
lymphomagenesis experiments as described above, using fetal
liver cells derived from E-myc transgenic animals, which
produce B cell lymphomas within 3–6 months of adoptive
transfer (26, 27). Expression of Cbx7 or Bmi-1 resulted in
lymphomas in the majority of recipient mice by 4–6 weeks (Fig.
3A, median tumor-free survival 43 days for E-myc/Cbx7 and 74
days for E-myc/Bmi-1 respectively; P  0.0001 for E-myc/
MSCV vs. E-myc/Cbx7 or E-myc/MSCV vs. E-myc/Bmi-1;
n 20, 26 and 23), and overall survival was similarly affected (SI
Fig. 8C). Importantly, all E-myc/Cbx7 and E-myc/Bmi-1
lymphomas analyzed were GFP-positive and overexpressed ei-
ther Cbx7 or Bmi-1 (data not shown).
Whole-body imaging (SI Fig. 8D) and pathological examina-
tion revealed that the E-myc/Cbx7 lymphomas were aggressive,
involving all major lymph node groups and causing splenomegaly
and thymic enlargement. Lymphomas disseminated to the liver,
lungs, kidneys, and occasionally the heart (Fig. 3B and data not
shown). All E-myc-derived lymphomas displayed a high pro-
liferative index as assessed by Ki67 staining (Fig. 3B). Immuno-
logical analysis showed that all of the E-myc/Cbx7 lymphomas
were of B cell origin (B220 positive), similar to that observed for
E-myc/GFP and all E-myc/Bmi-1 lymphomas. However, in
contrast with E-myc/GFP, all E-myc/Cbx7 and E-myc/Bmi-1
lymphomas tested presented with a mature B cell phenotype
(Thy1.2 B220 IgM; Fig. 3C), similar to the immunopheno-
type of E-myc/Ink4a/Arf/ lymphomas (12). These results
suggest that Cbx7 can both initiate and accelerate tumorigenesis.
The Ink4a/Arf Locus Is a Target of Cbx7 in Lymphomagenesis. In the
E-myc model, loss of Ink4a/Arf accelerates lymphomagenesis
mainly by disabling the Arf-p53 circuit and impacting p53-
dependent apoptosis (12, 28, 29). Because Cbx7 can repress
Ink4a/Arf transcription (16), we analyzed expression of p16Ink4a,
p19Arf and apoptosis in a panel of E-myc/MSCV, E-myc/
Cbx7, and E-myc/Bmi-1 lymphomas by quantitative RT-PCR
and TUNEL analysis of lymphoma sections. Control lymphomas
displayed a variable range in the expression of both Ink4a/Arf
transcripts and of apoptosis (see Fig. 4A for representative
TUNEL staining; 8/12 E-myc/MSCV lymphomas showed high
TUNEL staining, and four showed low levels of apoptosis).
However, lymphomas overexpressing either Cbx7 or Bmi-1
expressed low levels of p16Ink4a and p19Arf compared withMSCV
(Fig. 4B), and their levels of apoptosis were consistently low (Fig.
4A). Similarly, splenic lymphomas produced with Cbx7 as the
only exogenous transgene, expressed low levels of p16Ink4a and
p19Arf transcripts and p19Arf protein compared with normal
spleen, low levels of apoptosis (39/17 TUNEL-positive cells
per 400 field as compared with Fig. 4A) and low levels of p53
by IHC (SI Fig. 10). In addition, PCR performed using genomic
Fig. 2. Expression of Cbx7 in the murine lymphoid compartment causes mature T cell lymphomas. (A) Kaplan–Meier curve showing tumor-free survival. Mice
reconstituted with HSCs infected as indicated were monitored for lymphoma onset and illness until they reached a terminal stage and were killed. The data are
presented in a Kaplan–Meier format, showing the percentage of mouse survival at various times after reconstitution. (B) Characterization of Cbx7-overexpressing
lymphomas. Representative pictures are shown. (C) Western blot of Cbx7 overexpressing lymphomas showing exogenously expressed Cbx7 and endogenous
c-Myc levels. -Actin is used as a loading control. MEFs of the indicated genotypes and a lymphoma arising in a vav-MYC transgenic mouse were used as controls.
Scott et al. PNAS  March 27, 2007  vol. 104  no. 13  5391
CE
LL
BI
O
LO
G
Y
DNA from the two Cbx7-overexpressing lymphomas where
DNA was available showed no deletions of the Ink4a/Arf locus
(data not shown). Although it is difficult to infer a mechanism
from end-stage tumors that may have uncharacterized secondary
mutations, these results are consistent with our in vitro data (see
SI Fig. 9) and suggest that Cbx7 can suppress the Ink4a/Arf locus
and reduce apoptosis in vivo.
To directly test the genetic interactions between Cbx7, Ink4a/
Arf, and p53, we examined whether Cbx7 would confer a
proliferative advantage to cells already lacking Ink4a/Arf and
could diminish the selective pressure to disable the p53 pathway
during lymphomagenesis. Cbx7 and control retroviral vectors
(MSCV and Bmi-1) were introduced into enriched HSC cultures
from fetal livers of different genotypes (C57BL/6 WT, E-myc,
or Ink4a/Arf/), and the coexpressed GFP reporter was used to
monitor Cbx7 effects during proliferation and tumorigenesis.
Expression of Cbx7 conferred a growth advantage to fetal liver
cells derived from WT or E-myc embryos, as evidenced by a
notable in vitro expansion of GFP-positive cells (8-fold increase
within 1 week) that eventually overgrew their noninfected
(GFP-negative) counterparts (Fig. 4C and data not shown).
However, Cbx7 expression did not confer a growth advantage to
Ink4a/Arf/ fetal liver cells in vitro. Similarly, whereas all of the
Cbx7 and Bmi-1 lymphomas obtained after adoptive transfer of
WT or E-myc HSCs into recipient animals were GFP-positive,
none of the lymphomas arising from Ink4a/Arf-deficient HSC
populations expressed GFP (Fig. 4D; 3/3 Cbx7 and 2/2 Bmi-1
lymphomas). Finally, lymphomas arising from E-myc/p53/
HSCs expressing Cbx7 or Bmi-1 invariably retained the WT p53
allele, whereas those arising from MSCV-infected controls were
p53-null, because they lost this allele (Fig. 4E). Sequence analysis
of the retained p53 allele in the Cbx7 lymphomas confirmed it
to be WT (data not shown). Thus, Cbx7 requires Ink4a/Arf to
confer a selective advantage in vitro and in vivo, and the presence
of Cbx7 can compensate for p53 loss during the process of
lymphomagenesis.
Discussion
In this investigation, we used a bioinformatics prescreening
analysis followed by histopathology to narrow down the potential
relevant target cell type for CBX7-mediated oncogenesis to
lymphocytes and demonstrated that this PcG gene can transform
the lymphoid compartment in mice. Although the potential
contribution of other PcG genes to tumorigenesis has been
widely assumed (5, 7, 30), Cbx7 is a previously uncharacterized
example of a chromobox protein with potent oncogenic potential
in vivo. In follicular lymphoma, CBX7 up-regulation occurs
predominantly at the RNA level, although we did not identify a
mutational mode of oncogene activation in this study. Bmi-1 is
the only other PcG protein whose oncogenic properties have
been investigated and validated to a similar extent (10, 31). Of
note, although10% of mantle cell lymphomas (MCLs) amplify
10p12–13, where BMI-1 resides, many MCLs also up-regulate
BMI-1 transcript in the absence of genomic amplification (11).
Despite their structural (and presumably biochemical) differ-
ences, both BMI-1 and CBX7 are subunits of PRC1 complexes
repressing the transcription of the INK4a/ARF locus, and both
promote lymphomagenesis. However, BMI-1 and CBX7 appear
to exist in distinct complexes and can exert their effects inde-
pendently of each other (16). In keeping with these observations,
Bmi-1 protein levels were undetectable in E-myc/Cbx7 lym-
phomas, and conversely Cbx7 was not detected in E-myc/Bmi-1
lymphomas (data not shown). Importantly, as reported here,
BMI-1 and CBX7 also have different patterns of expression in
normal germinal centers and are associated with distinct lym-
phoma subtypes. Together, these results demonstrate that PcG
genes other than BMI-1 can be overtly oncogenic and could
contribute to various human pathologies.
In our experiments, hematopoietic progenitor cells trans-
duced with Cbx7 were subsequently used to reconstitute the
hematopoietic compartment of irradiated recipient mice. In the
absence of any other exogenously supplied oncogenic lesion,
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Cbx7 promotes T cell lymphomagenesis. However, when a
sensitizing oncogene is directed to the B cell compartment, Cbx7
promotes aggressive B cell lymphomagenesis with a penetrance
and latency similar to Bmi-1. Although the resulting lymphomas
are of a mature B cell type, they are distinct from human
follicular lymphoma in that they do not reflect a postgerminal
center origin (data not shown). Nevertheless, that Cbx7 coop-
erates with c-Myc in murine lymphomagenesis and is coex-
pressed with c-MYC in human follicular lymphomas reinforces
the relevance of our models to human disease.
Although CBX7 probably affects the transcription of multiple
genes, repression of the INK4a/ARF locus appears important for
its tumorigenic potential. Thus, like Ink4a/Arf loss, Cbx7 coop-
erates with c-Myc during lymphomagenesis. Furthermore, Cbx7
expression mimics Ink4a/Arf loss in murine fibroblasts and is
unable to further enhance the proliferative potential of Ink4a/
Arf/ hematopoietic progenitors. In these assays, the effects of
Cbx7 can be explained by its impact on Arf expression alone, but
in other contexts, suppression of p16Ink4a may also be important
(16). Similar mechanisms may be operating during the develop-
ment of human follicular lymphoma, where CBX7 levels are
often high but INK4a/ARF deletions and P53 mutations are rare
(32, 33). In human follicular lymphoma, where transformation to
a fatal, aggressive form can involve various lesions (34), CBX7
may act in conjunction with BCL-2 to restrict INK4a/ARF and
P53 activities, during the more indolent stages of this disease and
perhaps also during the process of transformation to diffuse
large B cell lymphomas. Consistent with this possibility, prelim-
inary studies suggest that coexpression of Bcl-2 with Cbx7
accelerates lymphomagenesis compared with expression of Cbx7
alone, although at this stage our data are not yet statistically
significant (P  0.06, unpublished observations).
Together with previous work, our studies reinforce the im-
portance of disabling the INK4a/ARF tumor surveillance during
tumorigenesis. For example, ZBTB7 (Pokemon) has also been
identified as a potent oncogene that can promote lymphomagen-
esis in mice and is up-regulated in human follicular lymphoma;
moreover, like CBX7, ZBTB7 is a negative regulator of ARF
(21). As shown here, CBX7 is often cooverexpressed with
ZBTB7 in human follicular lymphomas, raising the possibility
that these proteins act together to control expression from the
INK4a/ARF locus. However, based on its functional similarity to
BMI-1, it is also possible that CBX7 contributes to lym-
phomagenesis by enhancing stem cell self-renewal and/or in-
creasing the replicative potential of cancer stem cells. In either
case, CBX7 could be a target for control of follicular lymphoma
in the clinic.
Materials and Methods
Histopathology of Human Tumors and Tissues.We used the ONCO-
MINE database, version 1.0 (www.oncomine.org; ref. 35) to
analyze the expression of CBX7 in publicly available microarray
data, comparing normal tissue with cancer samples, and estab-
lished a P  0.05 as the cutoff limit for considering the data
significant. Graphics and statistic values from this analysis were
generated by using ONCOMINE. For IHC analysis, reactive
tonsils and tissue microarrays of follicular lymphoma and diffuse
large B cell lymphomas were stained with anti-BMI-1 (mouse
monoclonal; citric acid, pH 6.0, 1:50 dilution) or anti-CBX7
(rabbit polyclonal; citric acid, pH 6.0, 1:2,000 dilution) antibod-
ies. Antibodies were detected with a biotinylated anti-mouse or
-rabbit antibody and detected with a streptavidin detection
system or the PowerVision Detection system (ImmunoVision,
Springdale, AR). Criteria for scoring and analyzing CBX7
expression included approximate quantitation of percentage of
tumor cells that showed nuclear localization, which ranged from
5% to50%. Criteria for scoring BCL-2, CD10, Ki67, BCL-6,
and ZBTB7 expression was as published (21). Criteria for scoring
c-MYC included approximate quantization of percent tumor
cells showing nuclear localization which ranged from 0% (rare
scattered) to 5% of tumor cells. Statistical analyses for corre-
lations between various markers were performed by using
Fisher’s exact test.
Fig. 4. The Ink4a/Arf locus and p53 mediate Cbx7 effects in lymphomagen-
esis. (A) TUNEL analysis. Number of TUNEL-positive cells per 400 field is
shown. (B) Quantitative RT-PCR analysis of transcript levels for p19Arf and
p16Ink4a for lymphomas of the indicated genotypes. (C) Expression of Cbx7
confers a growth advantage on fetal liver cells obtained from WT or E-myc
embryos but not on those derived from Ink4a/Arf/ embryos, as measured by
the increase in GFP-positive cells after 7 days of in vitro culture. (D) Fetal liver
cells derived from embryos of genotypes as indicated were infected with the
named constructs coexpressing GFP and injected into irradiated mice. Result-
ing lymphomas were analyzed for GFP expression. (E) E-myc/p53/ fetal liver
cells were infected with the indicated constructs coexpressing GFP and in-
jected into irradiated mice. Loss of heterozygosity of p53 was analyzed by
allele-specific PCR in the resulting lymphomas.
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Generation of Lymphomas. Cell populations enriched for HSCs or
early progenitor cells of various genotypes were derived from
fetal livers at embryonic days 13.5–15.5 and infected with
retroviruses expressing various genes. Infected cells were used to
reconstitute the hematopoietic compartment of C57BL/6 mice
irradiated with a single 8-Gy-dose of total body -irradiation
(Cesium source; 0.8 Gy/min) (29). The retroviral vectors used in
this study were MSCV IRES GFP (referred as MSCV), MSCV
Cbx7 IRES GFP (referred as Cbx7), and MSCV Bmi-1 IRES
GFP (referred as Bmi-1). Mice were observed for lymphoma
onset with periodic palpation of peripheral lymph nodes, blood
smears, overall morbidity, and by whole-body fluorescence im-
aging. After the appearance of well palpable lymphomas, tumors
were harvested and either fixed for histological evaluation or
rendered as single-cell suspensions and used for different assays
or stored frozen in 10% DMSO. All mouse experiments were
performed according to protocols approved by Cold Spring
Harbor Laboratory. Statistical analysis was performed with a
one-way ANOVA test by using PRISM (Version 3.0, GraphPad,
San Diego, CA).
Histopathology and Immunophenotyping of Murine Tumors. Tissue
samples were fixed in 4% normal buffered formalin, embedded
in paraffin, sectioned into 5-m slices, and stained with hema-
toxylin/eosin. For IHC, the following antibodies were used: Ki67
(rabbit ab, Novocastra, Norwell, MA), p53 (rabbit ab, CM5,
Novocastra), CD3 (rabbit ab, DAKO Cytomation), and B220
(rat Ab, clone RA3–6B2, BD Biosciences PharMingen, Franklin
Lakes, NJ). Representative sections were deparaffinized, rehy-
drated in graded alcohols, and processed by using the avidin-
biotin immunoperoxidase method. Sections were then subjected
to antigen retrieval by using microwave heating on citric buffer
(except for the B220 Ab). Appropriate biotinylated secondary
antibodies (Vector Laboratories, Burlingame, CA) were used.
Diaminobenzidine was used as the chromogen, and hematoxylin
was used to counterstain nuclei. The apoptotic rate was analyzed
by TUNEL assay according to published protocols (29). For
immunophenotyping, samples were incubated with phyco-
erythrin or APC-Cy7-conjugated antibodies directed against
Thy1.2, B220, IgM, CD4, or CD3 (Pharmigen, San Diego, CA),
and data were collected on a LSRII flow cytometer equipped
with 488- and 635-nm lines (BD, San Jose, CA). Debris and dead
cells were gated out during analysis.
Western Blotting and Real-Time PCR.Both were performed by using
standard approaches, as described in SI Text.
Loss of Heterozygosity (LOH) Analysis of p53. E-myc/p53/ fetal
liver cells were obtained from embryos of crosses between
E-myc transgenic mice and p53/ mice, all on the C57BL/6
genetic background. Lymphomas were resected from tumor-
bearing mice and DNA prepared from FACS-sorted GFP-
positive B220-positive cells. LOH at the p53 locus was detected
by allele-specific PCR (29).
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